ASAM Criteria (Levels of Care)

The six dimensions

ASAM assessments rate a patient on six biopsychosocial dimensions on a 0–4 severity scale each. The combined picture, not any one dimension, drives placement.

1. Dimension 1 — Acute intoxication / withdrawal potential. Is the person currently intoxicated? Are they at risk of seizure, delirium tremens, or other withdrawal-related medical complications?
2. Dimension 2 — Biomedical conditions and complications. Active medical problems that could complicate treatment (pregnancy, liver disease, cardiac issues, chronic pain).
3. Dimension 3 — Emotional, behavioral, or cognitive conditions. Co-occurring mental-health diagnoses, suicidal ideation, psychosis. PHQ-9 + GAD-7 + PCL-5 commonly inform this dimension.
4. Dimension 4 — Readiness to change. Where is the person on the stages-of-change spectrum (precontemplation / contemplation / preparation / action / maintenance)?
5. Dimension 5 — Relapse, continued use, or continued problem potential. History of prior treatment episodes, recent relapse history, severity of cravings.
6. Dimension 6 — Recovery / living environment. Housing, social support, work, financial stability, exposure to triggers.

The nine levels of care

Once the six dimensions are scored, ASAM recommends one of these levels:

Why ASAM Criteria matter for insurance

Most insurance utilization-review processes for substance-use treatment use ASAM Criteria as the placement standard. To get inpatient (3.5+) authorization, the clinician's documentation has to support that ASAM dimensions justify it — typically dimension 1 (significant withdrawal risk) or dimension 6 (unsafe living environment that prevents outpatient success). If your plan denies a level, the appeal often turns on the ASAM Criteria narrative: did the clinician adequately document why the lower level wouldn't work?

ASAM Criteria in practice — how a placement decision actually happens

The six dimensions are not equally weighted in any individual case. The clinician synthesizes the picture and asks: "Given this combination, what's the LEAST RESTRICTIVE level that can safely treat this person?" The answer drives the placement.

Dimension 1 dominates if it's severe

A patient with severe alcohol withdrawal risk (history of seizures, current heavy chronic drinking, abnormal CIWA scores) goes to ASAM Level 3.7 or 4 (medically managed inpatient detox) regardless of how strong their support system is or how motivated they are. Withdrawal can kill — placement has to handle it. Once detox completes (typically 5–7 days), the patient steps DOWN to a less-restrictive level for ongoing rehabilitation.

Dimension 6 (environment) drives placement when other dimensions are moderate

A patient with moderate AUD, stable employment, supportive family, and a substance-free home environment is appropriately treated at ASAM 1 (outpatient) or 2.1 (IOP). The same patient living with active drug-using housemates needs ASAM 3.1 (clinically managed low-intensity residential) to break the use-environment loop — even if their disorder severity is identical to the first patient.

ASAM Criteria and insurance authorization

Insurance utilization-review processes use ASAM Criteria as the placement standard for substance-use treatment. The clinician's intake documentation has to support that ASAM dimensions justify the proposed level — typically Dimension 1 (significant withdrawal risk) or Dimension 6 (unsafe living environment that prevents outpatient success). Common authorization battles:

• Initial residential authorization. Insurer may push back: "Why not IOP?" Clinician must document specific Dimension findings — withdrawal risk score, suicide risk, housing instability, prior outpatient treatment failures. Generic "needs structure" is insufficient.
• Continued-stay reviews. Most insurers re-authorize residential in 7–14 day blocks. Each block requires updated ASAM documentation showing the patient still meets criteria for the level. Improvement in dimensions can trigger step-down recommendation; no improvement can trigger denial.
• Step-down recommendations. When the clinician believes the patient still needs residential but the insurer's clinical reviewer disagrees, the clinician can invoke a peer-to-peer (P2P) review. Many P2Ps are won by the clinician on the strength of dimension-specific documentation.
• Denials and appeals. Per Mental Health Parity Act, SUD treatment must be covered at parity with medical care. Denials based on stricter SUD-specific criteria are appealable. Documenting ASAM dimensions strengthens the appeal.

Common myths about ASAM levels

• "Higher ASAM level = better treatment." Not at all. The CORRECT level is the one that matches the patient's dimensions. Placing someone at ASAM 3.7 who only needs ASAM 2.1 is over-treatment — costlier, more disruptive to work and family, and not associated with better outcomes when the lower level was appropriate.
• "Detox = rehab." They're different ASAM phases. Detox (Level 3.7-WM or 4-WM, the WM = "withdrawal management") handles the physical withdrawal in 5–10 days. Rehab (Levels 1, 2.1, 2.5, 3.1, 3.5) is the longer rehabilitation work — relapse prevention, therapy, recovery skills. A 28-day inpatient program typically combines detox + rehab.
• "You have to go inpatient first." Not for most patients. About 60–70% of substance-use disorder treatment in the U.S. happens at outpatient levels (1 / 2.1 / 2.5). The default starting point should be the LEAST RESTRICTIVE level that matches the patient's dimensions, not the most restrictive.
• "Residential failed because the patient relapsed." Relapse is a known feature of substance-use disorder, not a treatment failure. Per McLellan 2000, addiction has relapse rates comparable to type 2 diabetes, hypertension, and asthma — none of which are considered "treatment failures" when symptoms recur.

Frequently Asked Questions